Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
No Thumbnail Available
Identifiers
Date
2018
Authors
Casali, P G
Bielack, S
Abecassis, N
Aro, H T
Bauer, S
Biagini, R
Bonvalot, S
Boukovinas, I
Bovee, J V M G
Brennan, B
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier BV
Abstract
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care of cancer patients) database [1]. Different bone tumour subtypes have distinct patterns of incidence, and each has no more than 0.3 incident cases per 100 000 per year. Osteosarcoma (OS) and Ewing sarcoma (ES) have a relatively high incidence in the second decade of life, whereas chondrosarcoma (CS) is more common in older age [2–4].
Description
MeSH Terms
Adult
Aftercare
Antineoplastic Combined Chemotherapy Protocols
Biopsy
Bone and Bones
Child
Humans
Incidence
Magnetic Resonance Imaging
Medical Oncology
Neoplasm Staging
Orthopedic Procedures
Patient Participation
Positron Emission Tomography Computed Tomography
Radiotherapy, Adjuvant
Self-Help Groups
Survivorship
Treatment Outcome
Aftercare
Antineoplastic Combined Chemotherapy Protocols
Biopsy
Bone and Bones
Child
Humans
Incidence
Magnetic Resonance Imaging
Medical Oncology
Neoplasm Staging
Orthopedic Procedures
Patient Participation
Positron Emission Tomography Computed Tomography
Radiotherapy, Adjuvant
Self-Help Groups
Survivorship
Treatment Outcome
DeCS Terms
Neoplasias
Incidencia
Huesos
Sarcoma de Ewing
Sistema de Registros
Pacientes
Sobrevida
Osteosarcoma
Condrosarcoma
Incidencia
Huesos
Sarcoma de Ewing
Sistema de Registros
Pacientes
Sobrevida
Osteosarcoma
Condrosarcoma
CIE Terms
Keywords
Age Factors, Bone Neoplasms, Europe, Long-Term Care, Neoadjuvant Therapy, Osteosarcoma, Radionuclide Imaging, Societies, Medical
Citation
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95.